

## PUBLICATIONS

### Peer-reviewed journal articles:

1. Cook D.G., Shaper A.G., Pocock S.J., **Kussick S.J.** Giving up smoking and the risk of heart attacks. A report from The British Regional Heart Study. *Lancet* 2: 1376-1380, 1986.
2. Cook D.G., **Kussick S.J.**, Shaper A.G. The respiratory benefits of stopping smoking. *J Smoking-Related Dis* 1: 45-58, 1990.
3. **Kussick S.J.**, Cooper J.A. Phosphorylation and regulatory effects of the carboxy terminus of a *Drosophila src* homolog. *Oncogene* 7: 1577-1586, 1992.
4. **Kussick S.J.**, Cooper J.A. Overexpressed *Drosophila src* 64B is phosphorylated at its carboxy-terminal tyrosine, but is not catalytically repressed, in cultured *Drosophila* cells. *Oncogene* 7: 2461-2470, 1992.
5. **Kussick S.J.**, Basler K., Cooper J.A. *Ras1*-dependent signaling by ectopically-expressed *Drosophila src* gene product in the embryo and developing eye. *Oncogene* 8: 2791-2803, 1993.
6. Cooper J.A., Simon M.A., **Kussick S.J.** Signaling by ectopically expressed *Drosophila Src64* requires the protein-tyrosine phosphatase *Corkscrew* and the adaptor downstream of receptor kinases. *Cell Growth Differen* 7: 1435-1441, 1996.
7. Adler H.T., Chinery R., Wu D.Y., **Kussick S.J.**, Payne J.M., Fornace A.J., Tkachuk D.C. Leukemic HRX fusion proteins inhibit GADD34-induced apoptosis and associate with the GADD34 and hSNF5/INI1 proteins. *Mol Cell Biol* 19: 7050-7060, 1999.
8. Lehr H.A., Hansen D.A., **Kussick S.**, Li M., Hwang H., Krummenauer F., Trouet S., Gown A.M. Assessment of proliferative activity in breast cancer: MIB-1 immunohistochemistry versus mitotic figure count. *Hum Pathol* 30: 1314-1320, 1999.
9. Sabath D.E., Wood B.L., **Kussick S.J.** PCR methods for determining B cell clonality. *J Mol Diagn* 2: 217-218, 2000.
10. **Kussick S.J.**, Wood B.L., Sabath D.E. Mature T cell leukemias which cannot be adequately classified under the new WHO classification of lymphoid neoplasms. *Leukemia* 16: 2457-2458, 2002.
11. Chang A.C., Benda P.M., Wood B.L., **Kussick S.J.** Lineage-specific identification of non-hematopoietic neoplasms by flow cytometry. *Am J Clin Pathol* 119: 643-655, 2003.

12. **Kussick S.J.**, Wood B.L. Using 4-color flow cytometry to identify abnormal myeloid populations. *Arch Pathol Lab Med* 127: 1140–1147, 2003.
13. **Kussick S.J.**, Wood B.L. Four-color flow cytometry identifies virtually all cytogenetically abnormal bone marrow samples in the workup of non-CML myeloproliferative disorders. *Am J Clin Pathol* 120: 854-865, 2003.
14. Sloan D.D., Zahariadis G., Posavad C.M., Pate N., **Kussick S.J.**, Jerome K.R. CTL are inactivated by herpes simplex virus-infected cells expressing a viral protein kinase. *J Immunol* 171: 6733-6741, 2003.
15. Stirewalt D.L., Meshinchi S., **Kussick S.J.**, Sheets K.M., Pogosova-Agadjanyan E., Willman C.L., Radich J.P. Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia. *Br J Haematol* 124: 481-484, 2004.
16. **Kussick S.J.**, Kalnoski M., Braziel R.M., Wood B.L. Prominent clonal B-cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. *Am J Clin Pathol* 121: 464-472, 2004.
17. Schmechel S., LeVasseur R.J., Yang K.H.-J., Koehler K.M., **Kussick S.J.**, Sabath D.E. Identification of genes whose expression patterns differ in benign lymphoid tissue and follicular, mantle cell, and small lymphocytic lymphoma. *Leukemia* 18: 841-855, 2004.
18. Ahmed S., **Kussick S.J.** Siddiqui A.K., Bhuiya T.A., Khan A., Sarewitz S., Steinberg H., Sison C.P., Rai K.R. Bronchial-associated lymphoid tissue lymphoma: A clinical study of a rare disease. *Eur J Cancer* 40: 1320-1326, 2004.
19. **Kussick S.J.**, Stirewalt D.L., Yi H.S., Sheets K.M., Pogosova-Agadjanyan E., Braswell S., Norwood T.H., Radich J.P., Wood B.L. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and Flt3 internal tandem duplication. *Leukemia* 18: 1591-1598, 2004.
20. Roberson R.S., **Kussick S.J.**, Vallieres E., Chen S.C., Wu D.Y. Escape from therapy-induced accelerated cellular senescence in p53 lung cancer cells and in human lung cancers. *Cancer Research* 65: 2795-2803, 2005.
21. Andrews J., Setran E., McDonnell L., **Kussick S.**, Wood B., Sabath D. An evaluation of the Cell Dyn 3200 for counting cells in cerebrospinal and other body fluids. *Lab Hematol* 11: 98-106, 2005.
22. Nixon B.K., **Kussick S.J.**, Carlon M.J., Rubin B.P. Intravascular large B-cell lymphoma involving hemangiomas: An unusual presentation of a rare neoplasm. *Mod Pathol* 18: 1121-1126, 2005.
23. **Kussick S.J.**, Fromm J.R., Rossini A.J., Li Y., Chang A., Norwood T.H., Wood B.L. Four-color flow cytometry shows strong concordance with bone marrow morphology

- and cytogenetics in the evaluation for myelodysplasia. *Am J Clin Pathol* 124: 170-181, 2005.
24. Yaziji H., Battifora H., Barry T.S., Hwang H.C., Bacchi C.E., McIntosh M.W., **Kussick S.J.**, Gown A.M. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. *Mod Pathol* 19: 514-523, 2006.
  25. Peri N., **Kussick S.**, Bakthavatsalam R., Mitsumori L., Dighe M. Postrenal transplant non-EBV multiple myeloma of donor origin. *Am J Transplant* 6: 419-422, 2006.
  26. Fromm J.R., **Kussick S.J.**, Wood B.L. Identification and purification of classical Hodgkin cells from lymph nodes by flow cytometry and flow cytometric cell sorting. *Am J Clin Pathol* 126: 764-780, 2006.
  27. Wood B.L., Arroz M., Barnett D., DiGiuseppe J., Greig B., **Kussick S.J.**, Oldaker T., Shenkin M., Stone E., Wallace P. 2006 Bethesda International Consensus Recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. *Cytometry B Clin Cytom* 72B: S14-S22, 2007.
  28. Gown A.M., Goldstein L.C., Barry T.S., **Kussick S.J.**, Kandalaf P.L., Kim P.M., Tse C.C. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. *Mod Pathol* 21: 1271-1277. Reply to Hanna et al. *Mod Pathol* 21: 1280-1281, 2008.
  29. Furmanczyk P.S., Wolgamot G.M., **Kussick S.J.**, Sabath D.E., Olerud J.E., Argenyi Z.B. Diagnosis of mycosis fungoides with different algorithmic approaches. *J Cutan Pathol* 37: 8-14, 2009.
  30. Tse C.H., Hwang H.C., Goldstein L.C., Kandalaf P.L., Wiley J.C., **Kussick S.J.**, Gown A.M. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: Implications for anti-HER2 targeted therapy. *J Clin Oncol* 29: 4168-4174, 2011.
  31. **ICSH/ICCS Workgroup**. Validation of cell-based fluorescence assays: practice guidelines from the International Council for Standardization of Haematology and International Clinical Cytometry Society. *Cytometry B Clin Cytom* 84: 281, 2013.
  32. Davis BH, Dasgupta A, **Kussick S**, Han JY, Estrellado A; ICSH/ICCS Working Group. Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part II - preanalytical issues. *Cytometry B Clin Cytom* 84: 286-290, 2013.

33. Mannelli L, Monti S, Love JE, **Kussick SJ**, McLuen A, Behnia F. Primary Rosai-Dorfman Disease of the Bone in a Patient With History of Breast Cancer: Appearance on 99mTc-MDP Scintigraphy, CT, and X-ray. *Clin Nucl Med* 40: 247-249, 2015
34. Chen J-H, Bai D, Dabhi V, Wood BL, **Kussick SJ**. Clinicopathologic features of primary colonic enteropathy-associated T cell lymphoma type II in an elderly Asian male with diarrhea. *J Hematopathol* 8: 37-41, 2015.
35. Keeney M, Halley JG, Rhoads DD, Ansari MQ, **Kussick SJ**, Karlon WJ, Mehta KU, Dorfman DM, Linden MA. Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists' Flow Cytometry Proficiency Testing Program. *Arch Pathol Lab Med* 139: 1276-1280, 2015.
36. Bohling SD, Thompson K, Davis E, **Kussick SJ**, Love J. Flow cytometric analysis of CD200 expression by pulmonary small cell carcinoma. *Cytometry B Clin Cytom.* In press, 2015.

Web-based peer-reviewed publication:

1. **Kussick S.J.**, Wood B.L. Bilineage T-lymphoblastic and myeloid blast transformation of chronic myelogenous leukemia, *Cases in Clinical Flow Cytometry*, volume 2 (electronic journal), 2002.

Non-peer-reviewed publications:

1. PhD Dissertation: **Kussick SJ**. A biochemical and genetic analysis of *Drosophila src*. 1992.
2. **Kussick S.J.** Review of Blood and Bone Marrow Pathology, edited by S. Wickramasinghe and J. McCullough. *Am J Clin Pathol* 121: 766-767, 2004.
3. **Kussick S.J.** Multiparametric Flow Cytometry in the Diagnosis of Myelodysplastic Syndromes and Related Disorders. *Lab Medicine* 38: 305-313, 2007.

Book Chapters:

1. **Kussick S.J.**, Cooper J.A. Preliminary biochemical studies of a *Drosophila* homolog of p60<sup>C-src</sup>. In Cellular Regulation by Protein Phosphorylation, NATO ASI Series, Vol. H56, ed. by L.M.G. Heilmeyer, Jr. Berlin, Springer-Verlag, 295-299, 1991.
2. **Kussick S.J.**, Cooper J.A. Regulation and functions of *src*-family kinases: An update. In Tyrosine Phosphorylation/Dephosphorylation and Downstream

Signaling, NATO ASI Series, Vol. H76, ed. by L.M.G. Heilmeyer Jr. Berlin, Springer-Verlag, 11-30, 1993.

3. **Kussick S.J.** Flow cytometry in the diagnosis of benign and malignant hematopoietic diseases. In Wintrobe's Atlas of Clinical Hematology, ed. by D.C. Tkachuk and J.V. Hirschmann. Philadelphia, PA, Lippincott Williams & Wilkins, Chapter 6: 211-238, 2007.
4. **Kussick S.J.** Flow cytometric principles in hematopathology. In Hematopathology, 2<sup>nd</sup> Edition, ed. by E. Hsi, series ed. J.R. Goldblum. Philadelphia, PA, Saunders, Elsevier, Chapter 23, 2012.

Abstracts and/or Proceedings:

1. Cook D.G., **Kussick S.J.**, Shaper A.G. Ex-smoking and ischemic heart disease in British men. *European Heart Journal (Suppl 1)*: 7, 1986.
2. **Kussick S.J.**, Cooper J.A. Drosophila *src* behaves like an activated tyrosine kinase when overexpressed in Drosophila Schneider 2 cells. *J Cell Biochem (Suppl 16B)*: 211, 1992.
3. **Kussick S.J.**, Chang K., Pastan I., Gown A. Monoclonal antibody K1 is a highly sensitive and relatively specific marker for papillary serous ovarian carcinoma in deparaffinized, formalin-fixed tissue. *Mod Pathol* 9: 93A, 1996.
4. **Kussick S.J.**, Tkachuk D.C. The leukemia-associated protein HRX binds to the oncoprotein MDM2. *Am J Clin Pathol* 110: 117, 1998.
5. Adler H.T., Chinery R., Wu D.Y., **Kussick S.J.**, Tkachuk D.C. Leukemic HRX fusion proteins abrogate DNA-damage induced apoptosis. *Blood* 92 (Suppl 1): 509a, 1998.
6. **Kussick S.J.**, Tkachuk D.C. The leukemia-associated protein HRX binds to the oncoprotein MDM2. *Blood* 92 (Suppl 1): 68a, 1998.
7. **Kussick S.J.**, Chinery R., Tkachuk D.C. Leukemia-associated HRX fusion proteins inhibit p53-dependent apoptosis and transcriptional activity. *Blood* 94 (Suppl 1): 52a, 1999.
8. Reyes V., **Kussick S.J.** Immunohistochemical analysis of CD4 and CD8-positive subpopulations in T cell neoplasms: a comparison with frozen section immunoperoxidase, flow cytometry, and PCR. *Mod Pathol* 13: 161A, 2000.
9. **Kussick S.J.**, Wood B.L. Clonal B cell populations identified by flow cytometry in histologically-reactive lymphoid proliferations. *Mod Pathol* 14: 169A, 2001.

10. Edmonson P., Wood B.L., **Kussick S.J.** Patterns of surface antigen expression in T-cell large granular lymphocytic leukemia. *Am J Clin Pathol* 116: 279, 2001.
11. **Kussick S.J.**, Wood B.L., Li Y. Using antibodies to CD56 and CD45 to identify nonhematopoietic small blue round cell tumors by flow cytometry. *Am J Clin Pathol* 116: 279, 2001.
12. Ahmed S., **Kussick S.J.**, Karim A. Low-grade B-cell bronchial-associated lymphoid tissue (BALT) lymphoma: A descriptive natural history of a rare disease. *Blood* 98: 337a, 2001.
13. **Kussick S.J.**, Wood B.L., Liu A., True L.D. Flow cytometric evaluation can distinguish between benign and neoplastic prostatic epithelium. *Mod Pathol* 15: 168A, 2002.
14. Li Y.L., **Kussick S.J.**, Sabath D.E., Wood B.L. Immunophenotyping of chronic lymphocytic leukemia/small lymphocytic lymphoma for expression of CD27, IgD, IgM and CD38. *Mod Pathol* 15: 250A, 2002.
15. **Kussick S.J.**, Wood B.L. Flow cytometry demonstrates superior sensitivity to conventional cytogenetics in identifying abnormal myeloid populations in non-CML myeloproliferative disorders. *Mod Pathol* 15: 249A, 2002.
16. Palomares M.R., **Kussick S.J.**, Koehler K.M., Sabath D.E. Development of a method to quantify breast cancer cells in the peripheral blood: comparison of quantitative real-time RT-PCR and flow cytometry using positive versus negative epithelial enrichment methods. Presented at the 2<sup>nd</sup> International NCI EORTC Meeting on Cancer Diagnostics, Washington, DC, June 26-29, 2002.
17. **Kussick S.J.**, Yi H.S., Gerard A.A., Wood B.L. Acute myeloid leukemia bearing the Flt3 internal tandem duplication has a unique immunophenotype which enables its identification by flow cytometry. *Blood* 100: 196a, 2002.
18. **Kussick S.J.**, Li Y., Chang A., Norwood T.H., Wood B.L. Flow cytometric evaluation for myelodysplasia identifies nearly all cytogenetically abnormal bone marrows: an evaluation of 263 cases. *Blood* 100: 790a, 2002.
19. Nixon B., Rubin B.P., **Kussick S.J.**, Carlon M. Intravascular large B cell lymphoma involving a capillary hemangioma: An unusual presentation of a rare neoplasm. *Mod Pathol* 16: 96A, 2003.
20. Chang A., Benda P.M., Wood B.L., **Kussick S.J.** Flow cytometric diagnosis of nonhematopoietic neoplasms. *Mod Pathol* 16: 320A, 2003.

21. Stirewalt D., Pogosova-Agadjanyan E., Khalid N., **Kussick S.J.**, Ladne P., Sheets K.M., Zhao L.P., Radich J.P. Gene expression differences between AML cells and normal CD34+ bone marrow cells. *Blood* 102: 194b, 2003.
22. Gu Y., Blasi J., Lee J., Schwartz J.L., **Kussick S.J.**, Rubin B.P. Atm haploinsufficiency unmasks spontaneous myeloid neoplasms in a murine Scid model. *Blood* 102: 344b, 2003.
23. **Kussick S.J.**, Fromm J., Rossini A.J., Norwood T.H., Chang A., Li Y., Wood B.L. Four-color flow cytometric evaluation for myelodysplasia identifies nearly all morphologically- and cytogenetically-abnormal bone marrows. Presented at the International Society for Analytical Cytology XXII International Congress, Montpellier, France, May 22-27, 2004.
24. Mendelin J.E., Stirewalt D.L., Yi H.S., Sheets K.M., Radich J.P., Wood B.L., **Kussick S.J.** Acute myeloid leukemias bearing the Flt3 internal tandem duplication have a characteristic immunophenotype not shared by acute myeloid leukemias with activation point mutations in Flt3 or Ras genes. Presented at the 39<sup>th</sup> Annual Meeting of the Academy of Clinical Laboratory Physicians and Scientists, Denver, CO, June 3-5, 2004.
25. Fromm J.R., **Kussick S.J.**, Wood B.L. Identification and purification of Hodgkin cells from lymph nodes involved by classical Hodgkin lymphoma by flow cytometry and flow cytometric cell sorting. *Breast Cancer Res Treat* 100 (Suppl 1), 2006. (Poster presentation at 29<sup>th</sup> Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 2006)
26. Gown A.M., Goldstein L.C., Barry T.S., **Kussick S.J.**, Kandalaf P.L. Extremely high concordance between immunohistochemistry and FISH testing for HER-2/neu status in breast cancer: a study of 6720 cases. *Breast Cancer Res Treat* 100 (Supplement 1): S218, 2006. (Poster presentation at 29<sup>th</sup> Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 2006)
27. Jokinen C., Li N., Wolgamot G., **Kussick S.J.**, Wood B.L., Olerud J., Argenyi Z. Florid CD1a+ dermal dendritic cells in primary cutaneous CD30+ lymphoproliferative disorders, mimicking Langerhans cell histiocytosis. *J Cutan Pathol* 33: 92, 2006.
28. Kandalaf P.L., Barry T.S., **Kussick S.J.**, Goldstein L.C., Bacchi C., Bitterman P., Gown A.M. Immunohistochemical detection of Aquaporin 1 as an aid in identifying renal cell carcinoma in the setting of metastatic carcinomas of unknown primary. *Mod Pathol* 19: 144A, 2006. (Poster presentation at the Annual Meeting of United States and Canadian Academy of Pathology, Atlanta, GA, February 2006)
29. **Kussick S.J.**, Ceniza D., Oppenlander B.K., Barry T.S., Gown A.M. Nine-color/eleven-parameter flow cytometry can be utilized in the clinical laboratory to

diagnose a broad range of hematolymphoid neoplasms. *Mod Pathol* 19: 330A, 2006. (Poster presentation at the Annual Meeting of United States and Canadian Academy of Pathology, Atlanta, GA, February 2006)

30. Barry T.S., Kim P.M., Treaba D.O., Tirrell S.E., **Kussick S.J.**, Tse C.H., Kandalaft P.L., Gown A.M. Use of p57KIP2 and Ki-67 immunohistochemistry and interphase FISH in the diagnosis of hydatidiform Mole: A unique algorithmic approach. *Mod Pathol* 20 (S2): 189A-190A, 2007. (Platform presentation at the Annual Meeting of the United States and Canadian Academy of Pathology, San Diego, CA, March 2007)
31. Barry T.S., Tse C., Goldstein L.C., Kim P.M., **Kussick S.J.**, Kandalaft P., Gown A.M. Quality control procedures are essential in accurate HER2 FISH testing using automated morphometric image analysis. *Breast Cancer Res Treat* 2007. (Poster presentation at 30<sup>th</sup> Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 2007)
32. Goldstein L.C., Tirrell S.E., Barry T.S., **Kussick S.J.**, Kandalaft P.L., Kim P.M., Gown A.M. Immunophenotypic profile of the basal-like subtype of invasive breast carcinomas: influence on diagnosis and therapy. *Mod Pathol* 20 (S2): 32A-33A, 2007. (Platform presentation at the Annual Meeting of the United States and Canadian Academy of Pathology, San Diego, CA, March 2007)
33. Kim P.M., Goldstein L.C., Barry T.S., **Kussick S.J.**, Kandalaft P.L., Gown A.M. Extremely high concordance between immunohistochemistry and FISH testing for HER2 status using subtraction methodology scoring in breast cancer: a study of 5942 cases. *Mod Pathol* 20 (S2): 38A-39A, 2007. (Platform presentation at the Annual Meeting of the United States and Canadian Academy of Pathology, San Diego, CA, March 2007)
34. Furmanczyk P.S., Wolgamot G.M., **Kussick S.J.**, Sabath D.E., Olerud J.E., Argenyi Z.B. Diagnosis of mycosis fungoides with different algorithmic approaches. *Mod Pathol* 21 (S1): 94A-34A, 2008. (Poster presentation at the Annual Meeting of the United States and Canadian Academy of Pathology, Denver, CO, March 2008)
35. Gown A.M., Goldstein L.C., Barry T.S., Kandalaft P.L., **Kussick S.J.**, Tse C.C. Choice of primary anti-HER2 antibody affects concordance of immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) for determination of breast cancer HER2 status. *Mod Pathol* 21 (S1): 33A-34A, 2008. (Platform presentation at the Annual Meeting of the United States and Canadian Academy of Pathology, Denver, CO, March 2008)
36. Shaw A.J., Goldstein L.C., Kandalaft P.L., Hwang H.C., **Kussick S.J.**, Gown A.M. Comparative and additive sensitivities of immunohistochemical markers of breast cancer using new monoclonal antibodies to GCDPF-15 and mammaglobin. *Mod*



Pathol 22: 67A, 2009. (Platform presentation at the Annual Meeting of the United States and Canadian Academy of Pathology, Boston, MA, March 2009)

37. Shaw A.J., Gown A.M., Hwang H.C., Kandalaf P.L., Goldstein L.C., **Kussick S.J.** Bcl-6 coexpression in Mantle cell lymphoma: A rare finding associated with a lack of CD5 and/or CD3 coexpression. *Mod Pathol* 22: 286A, 2009. (Poster presentation at the Annual Meeting of the United States and Canadian Academy of Pathology, Boston, MA, March 2009)
38. Tse C.H., Gown A.M., Goldstein L.C., Kandalaf P.L., Baird G., **Kussick S.J.**, Barry T.S. Amplification involving the CEP17 region may lead to false negative results of HER2 gene amplification by FISH. *Cancer Res* 69 (Suppl 2): 1079, 2009. (Poster presentation at the 31<sup>st</sup> Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 2008)
39. Gown A.M., Goldstein L.C., Kandalaf P.L., Hwang H.C., **Kussick S.J.**, Tse C.C. Markers of metastatic breast cancer: Correlations between GCDFP-15 or mammaglobin expression and tumor grade, hormone receptor, and HER2 expression. (Poster presentation at the Annual Meeting of the United States and Canadian Academy of Pathology, Washington, DC, March 2010)
40. Said, J.W., Reeves, J.A., Flinn, I., Tulpule, A., Robles, R.L., Flowers, C., DiBella, N.J., Kolibaba, K.S., Venugopal, P., Kolevska, T., De Vos, S., Jaye, D.L., Esseltine, D., Mulligan, G., Corvez, M.M., Eckardt, J.R., Brockman, B., Chico, I.M., Leonard, J., **Kussick, S.J.** Certification and role of local pathologists for diffuse large B-cell lymphoma (DLBCL) subtyping and eligibility determination in the phase II PYRAMID study. (Abstract 8559 at the Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 2013)